AstraZeneca’s Calquence improves chronic lymphocytic leukaemia

eAwazMedicine

London – Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukaemia (CLL). For the secondary …

AstraZeneca advances scientific leadership in haematology at ASH 2023

eAwazHealth

London – AstraZeneca will present new clinical and real-world data in multiple haematological conditions at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 9 to 12 December 2023. A total of 63 abstracts will feature 14 approved and potential new medicines across the Company’s portfolio and pipeline including from Alexion, AstraZeneca’s Rare Disease …